Artwork

Content provided by Sue Bevan - Society for Epidemiologic Research (SER). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sue Bevan - Society for Epidemiologic Research (SER) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Epidemiology Counts – Episode 39 – Alzheimer’s Disease and Dementia

1:05:27
 
Share
 

Manage episode 354884854 series 2509208
Content provided by Sue Bevan - Society for Epidemiologic Research (SER). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sue Bevan - Society for Epidemiologic Research (SER) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode of Epi Counts, host Bryan James talks to Maria Glymour, the incoming chair of the Department of Epidemiology at Boston University School of Public Health, about their shared area of research: the epidemiology of Alzheimer’s disease and dementia. In this conversation, they discuss the latest on how scientists are attempting to define Alzheimer’s disease biologically as a distinct concept from the dementia syndrome, as well as the controversies surrounding such a definition. They cover what the evidence says about what we can do to prevent dementia, and what aspects of Alzheimer’s and dementia make these conditions particularly difficult to study. Finally, they address the cautious excitement regarding the recent FDA approval of two new Alzheimer’s drugs that appear to target the underlying disease after decades of failed trials, and the societal, ethical, and financial implications that arise from the introduction of these therapies.

Show notes:
Alzheimer’s Association Facts & Figures report https://www.alz.org/alzheimers-dementia/facts-figures

  continue reading

43 episodes

Artwork
iconShare
 
Manage episode 354884854 series 2509208
Content provided by Sue Bevan - Society for Epidemiologic Research (SER). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sue Bevan - Society for Epidemiologic Research (SER) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode of Epi Counts, host Bryan James talks to Maria Glymour, the incoming chair of the Department of Epidemiology at Boston University School of Public Health, about their shared area of research: the epidemiology of Alzheimer’s disease and dementia. In this conversation, they discuss the latest on how scientists are attempting to define Alzheimer’s disease biologically as a distinct concept from the dementia syndrome, as well as the controversies surrounding such a definition. They cover what the evidence says about what we can do to prevent dementia, and what aspects of Alzheimer’s and dementia make these conditions particularly difficult to study. Finally, they address the cautious excitement regarding the recent FDA approval of two new Alzheimer’s drugs that appear to target the underlying disease after decades of failed trials, and the societal, ethical, and financial implications that arise from the introduction of these therapies.

Show notes:
Alzheimer’s Association Facts & Figures report https://www.alz.org/alzheimers-dementia/facts-figures

  continue reading

43 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide